DKY709

Overview

DKY709 is an investigational small-molecule degrader targeting IKZF2 (Helios; IKZF2), a transcription factor that stabilizes regulatory T cell (Treg) suppressive function. By degrading Helios, DKY709 is designed to reprogram intratumoral Tregs and relieve immunosuppression in the tumor microenvironment.

Evidence in the corpus

• Cited among IKZF2 degraders (alongside PLX-4545) under clinical investigation to reprogram Tregs in R/M NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.